reviewed april 2026|next review october 2026|88 physicians psi has verified|27 published studies
KPV
The tripeptide Lys-Pro-Val (KPV) is a three-amino-acid fragment of alpha-MSH (alpha-melanocyte-stimulating hormone) that inhibits NF-kB (nuclear factor kappa-B) without activating melanocortin receptors, with replicated gut inflammation findings across multiple independent groups and demonstrated oral bioavailability through the PepT1 intestinal transporter.
Evidence landscape: 27 published studies
27 published items. 0 human studies and 20 animal studies. A focused evidence base with replicated gut inflammation findings across independent groups.
- 20 Animal
- 7 Reviews
NF-kB inhibition without melanocortin receptor activation. Separates the anti-inflammatory mechanism from pigmentation and cardiovascular effects of the parent molecule.
Oral bioavailability demonstrated through the PepT1 (SLC15A1) peptide transporter in cell culture and animal models. Unusual for any peptide.
No human clinical trial has been conducted for any indication. All evidence comes from cell culture and animal studies.
PSI Assessment
A three-amino-acid fragment that blocks one of the master switches of inflammation - and unlike most peptides, animal studies suggest it works when taken orally. KPV inhibits NF-kB without activating the melanocortin receptors responsible for pigmentation and cardiovascular effects. The gut inflammation data is consistent across multiple independent groups using different colitis models. But this is entirely research in animal models. No human clinical trial has been conducted for any indication. Here is what the evidence supports and where it stops.
Inhibits NF-kB without melanocortin receptor activation. Oral bioavailability through the PepT1 transporter. No human clinical trial has been conducted.
The mechanism is direct NF-kB inhibition through prevention of IkB-alpha phosphorylation, keeping the NF-kB transcription factor sequestered in the cytoplasm where it cannot drive inflammatory gene expression. Unlike the parent molecule alpha-MSH, KPV does not bind melanocortin receptors with significant affinity, meaning it does not produce pigmentation, cardiovascular, or sexual function effects. The oral bioavailability finding, that KPV enters intestinal epithelial cells through the PepT1 (SLC15A1) peptide transporter, is unusual for any peptide and is the primary differentiator for gut inflammation applications.
What the evidence supports
KPV inhibits NF-kB signaling without activating melanocortin receptors, isolating the anti-inflammatory mechanism from the parent alpha-MSH molecule. Gut inflammation reduction is replicated across multiple independent groups using different colitis models. Oral bioavailability through the PepT1 intestinal transporter is demonstrated in cell culture models and animal studies.
What is not yet established
Whether KPV produces clinically meaningful anti-inflammatory effects in humans. No human clinical trial has been conducted for any indication. Whether oral bioavailability in animal models translates to therapeutic concentrations in the human gut. Long-term safety data.
Research Evidence
The findings below cover the NF-kB inhibition mechanism, gut inflammation data, and the oral bioavailability finding.
Evidence by condition
Evidence dimensions across KPV's investigated applications. Gut inflammation has the most consistent data. All evidence is from animal studies and cell culture.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Gut Inflammation/IBD | ||||
| Skin Inflammation | ||||
| General Anti-Inflammatory | ||||
| Antimicrobial |
KPV inhibits NF-kB signaling by preventing IkB-alpha phosphorylation, keeping the inflammatory transcription factor sequestered in the cytoplasm. This reduces production of TNF-alpha, IL-1-beta, and IL-6 in cell and animal models.
The NF-kB inhibition mechanism is well-characterized and replicated across independent groups.
Gut inflammation reduction is replicated across DSS-induced and TNBS-induced colitis models by multiple independent groups. Oral administration was effective in several models.
The replication across different colitis induction methods and independent laboratories strengthens the signal for gut inflammation specifically.
Oral bioavailability through the PepT1 (SLC15A1) peptide transporter is demonstrated in Caco-2 cell monolayers and animal intestinal tissue.
Most peptides are degraded in the GI tract. KPV's ability to enter cells through PepT1 is a differentiating feature that could simplify delivery if validated in humans.
0 Human|20 Animal|7 Reviews
View all 27 indexed studiesHow KPV Works
KPV is a C-terminal tripeptide (Lys-Pro-Val) fragment of alpha-melanocyte-stimulating hormone. It is only three amino acids long but retains the anti-inflammatory signaling of the parent molecule.
KPV works by blocking one of your body's main inflammation switches, a protein called NF-kB. When NF-kB is active, it tells your cells to produce inflammatory signals. KPV enters cells and prevents NF-kB from reaching the nucleus where it would turn on those inflammatory genes. The result in animal studies is less inflammation at the tissue level, particularly in the gut lining.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
KPV inhibits NF-kB nuclear translocation by preventing IkB-alpha phosphorylation and degradation, which keeps the NF-kB complex sequestered in the cytoplasm. This reduces transcription of pro-inflammatory cytokines including TNF-alpha, IL-1-beta, and IL-6. The peptide enters intestinal epithelial cells through the PepT1 (SLC15A1) peptide transporter, which is significant because it provides a potential oral delivery route that most peptides lack. KPV retains the anti-inflammatory signaling of full-length alpha-MSH without activating melanocortin receptors responsible for pigmentation or cardiovascular effects.
What is KPV being studied for?
Researchers are studying KPV across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for KPV overall. This means a compound can have human studies for one condition but only animal data for another.
Gut Inflammation/IBD
·Animal StudiesMultiple animal studies using DSS-induced and TNBS-induced colitis models show KPV reduces inflammation scores, decreases pro-inflammatory cytokine levels, and improves mucosal integrity. Oral administration was effective.
Limitations: All data is from animal colitis models. No human IBD trials exist. Whether oral KPV achieves therapeutic concentrations in human intestinal tissue is unknown.
Skin Inflammation
·Animal StudiesAnimal studies show KPV reduces skin inflammation in dermatitis models through the same NF-kB inhibition pathway observed in gut tissue.
Limitations: Limited to animal dermatitis models. No human skin inflammation trials. Optimal topical formulation not established.
General Anti-Inflammatory
·Animal StudiesThe NF-kB inhibition mechanism provides broad anti-inflammatory activity observed across multiple tissue types in studies using animal models.
Limitations: Broad anti-inflammatory activity in cell and animal models does not predict human therapeutic utility. Many NF-kB inhibitors have failed to translate from animal models to clinical success.
Antimicrobial
·PreclinicalLimited evidence suggests alpha-MSH-derived peptides including KPV may have direct antimicrobial properties, though this is not the primary research focus.
Limitations: Very limited data. Not a primary research focus for KPV.
Safety and Regulatory Status
FDA Status: Not FDA-approved for any indication.
Availability: Not currently listed on any FDA pharmacy preparation lists. Available as a research compound.
Safety context: Derived from alpha-MSH, a naturally occurring (the body's own) peptide. Does not activate melanocortin receptors, meaning no pigmentation or cardiovascular effects observed in studies using animal models.
No human safety data exists. Animal studies have not reported adverse effects. The compound lacks the melanogenic and cardiovascular side effects of full-length alpha-MSH.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a KPV discussion.
Comparison and Related Research
KPV is most often compared with other compounds studied for gut inflammation and tissue protection.
Head-to-head comparisons
Full research comparisons covering KPV and another peptide side by side.
KPV vs BPC-157
BPC-157 has extensive gut research. KPV has anti-inflammatory mechanisms but less direct gut evidence. Evidence-graded comparison for gut healing peptides.
View full comparisonKPV vs LL-37
KPV reduces inflammation via NF-kB. LL-37 kills pathogens directly. Both are early-stage. Evidence-graded comparison of two immune peptides.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.This study demonstrated that the tripeptide KPV (Lys-Pro-Val), derived from the C-terminal end of alpha-MSH, is actively transported into intestinal epithelial cells via the PepT1 peptide transporter. Once inside the cell, KPV inhibited NF-kB activation and reduced pro-inflammatory cytokine production. In mouse models of colitis, oral KPV administration significantly reduced intestinal inflammation, suggesting a mechanism for oral delivery of this anti-inflammatory peptide.Dalmasso G et al., 2008 in Gastroenterology. View on PubMed
- 2.This study evaluated KPV in two distinct mouse models of inflammatory bowel disease: DSS-induced colitis and the CD4+CD45RBhigh T cell transfer model. In both models, KPV treatment reduced disease activity scores, colonic inflammation, and pro-inflammatory cytokine levels. The findings extended the evidence for KPV's anti-inflammatory activity to immune-mediated models of IBD.Kannengiesser K et al., 2008 in Inflamm Bowel Dis. View on PubMed
- 3.A review examining alpha-MSH and its derived peptides, including KPV, as a novel class of anti-inflammatory compounds. The paper details how KPV retains the core anti-inflammatory activity of the full-length alpha-MSH molecule despite being only three amino acids long. The review covers evidence from models of skin inflammation, arthritis, and bowel disease, and discusses the potential for clinical translation.Luger TA et al., 2007 in Ann Rheum Dis. View on PubMed
- 4.A comprehensive review of alpha-MSH and its C-terminal tripeptide KPV, covering their biochemistry, receptor pharmacology, and anti-inflammatory effects across multiple organ systems. The review details how KPV modulates immune cell function by suppressing NF-kB-dependent inflammatory pathways and provides an overview of preclinical evidence supporting therapeutic development for conditions including IBD, dermatitis, and arthritis.Brzoska T et al., 2008 in Endocr Rev. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.